Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Widge, A. T., Rouphael, N. G., Jackson, L. A., Anderson, E. J., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2032195 · Cited by 722

Neutralizing Activity of BNT162b2-Elicited Serum

Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C. R., Swanson, K. A., Cai, H., Sarkar, R., Chen, W., Cutler, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2102017 · Cited by 537

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Suthar, M. S., Zimmerman, M. G., Kauffman, R. C., Mantus, G., Linderman, S. L., Hudson, W. H., Vanderheiden, A., Nyhoff, L., Davis, C. W., Adekunle, O., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100040 · Cited by 508

Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing Antibodies

Vanderheiden, A., Edara, V. V., Floyd, K. A., Kauffman, R. C., Mantus, G. E., Anderson, E. J., Rouphael, N., Edupuganti, S., Shi, P., Menachery, V. D., et al. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.116 · Cited by 134

The biological and clinical significance of emerging SARS-CoV-2 variants

Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Kennedy, N. A., Lin, S., Goodhand, J., Chanchlani, N., Hamilton, B., Bewshea, C., Nice, R., Chee, D., Cummings, F. J. R., Fraser, A., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324789 · Cited by 270

The glycosylation in SARS-CoV-2 and its receptor ACE2

Gong, Y., Qin, S., Dai, L., & Tian, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00809-8 · Cited by 226

The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines

McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 195

SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63

Woldemeskel, B. A., Garliss, C. C., & Blankson, J. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149335 · Cited by 175

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153

Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects

Wheeler, S., Shurin, G. V., Yost, M., Anderson, A., Pinto, L., Wells, A. H., & Shurin, M. R. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00341-21 · Cited by 156

COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries

Wong, L. P., Alias, H., Danaee, M., Ahmed, J., Lachyan, A. S., Cai, C. Z., Lin, Y., Hu, Z., Tan, S. Y., Lu, Y., et al. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00900-w · Cited by 134

To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination

Chiu, N., Chi, H., Tu, Y., Huang, Y.-N., Tai, Y., Weng, S.-L., Chang, L., Huang, D. T., Huang, F.-Y., & Lin, C. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1971522 · Cited by 117

Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Bozio, C. H., Grannis, S. J., Naleway, A. L., Ong, T. C., Butterfield, K. A., DeSilva, M. B., Natarajan, K., Yang, D., Rao, S., Klein, N. P., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7044e1 · Cited by 90

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers

Padoan, A., Dall’Olmo, L., Rocca, F. D., Barbaro, F., Cosma, C., Basso, D., Cattelan, A. M., Cianci, V., & Plebani, M. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.04.006 · Cited by 79

Immune response to SARS-CoV-2 infection and vaccination in patients receiving kidney replacement therapy

Ikizler, T. A., Coates, P. T., Rovin, B. H., & Ronco, P. M. (2021) · Kidney International · doi:10.1016/j.kint.2021.04.007 · Cited by 71

Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies

Noori, M., Nejadghaderi, S. A., Arshi, S., Carson‐Chahhoud, K., Ansarin, K., Kolahi, A., & Safiri, S. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2277 · Cited by 64

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Gagné, M., Flynn, B. J., Andrew, S. F., Marquez, J., Flebbe, D. R., Mychalowych, A., Lamb, E., Davis-Gardner, M. E., Burnett, M. R., Serebryannyy, L., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01951-5 · Cited by 78

Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models

Banihashemi, S. R., Es‐haghi, A., Mehrabadi, M. H. F., Noofeli, M., Mokarram, A. R., Ranjbar, A., Salman, Μ. D., Hajimoradi, M., Razaz, S. H., Taghdiri, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836745 · Cited by 48

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variantsPreprint

Pegu, A., O’Connell, S. E., Schmidt, S. D., O'Dell, S. J., Talana, C. A., Lai, L., Albert, J., Anderson, E. J., Bennett, H., Corbett, K. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.13.444010 · Cited by 50

Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma

Nooka, A. K., Shanmugasundaram, U., Cheedarla, N., Verkerke, H., Edara, V. V., Valanparambil, R. M., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Lonial, S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02257 · Cited by 46

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617

Peng, L., Hu, Y., Mankowski, M. C., Ren, P., Chen, R. E., Wei, J., Zhao, M., Li, T., Tripler, T. N., Ye, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29288-3 · Cited by 43

Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern

Yu, X., Wei, D., Xu, W., Liu, C., Guo, W., Li, X., Tan, W., Liu, L., Zhang, X., Qu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29477-0 · Cited by 38

AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans

Grigoryan, L., Feng, Y., Bellusci, L., Lai, L., Wali, B., Ellis, M. L., Yuan, M., Arunachalam, P. S., Hu, M., Kowli, S., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi8039 · Cited by 43

Advanced Materials for SARS‐CoV‐2 Vaccines

Mabrouk, M. T., Huang, W., Martínez‐Sobrido, L., & Lovell, J. F. (2021) · Advanced Materials · doi:10.1002/adma.202107781 · Cited by 38

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies

Focosi, D., Tuccori, M., Baj, A., & Maggi, F. (2021) · Viruses · doi:10.3390/v13071211 · Cited by 37

SARS-CoV-2-antibody response in health care workers after vaccination or natural infection in a longitudinal observational study

Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.081 · Cited by 38

SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response

Mileto, D., Fenizia, C., Cutrera, M., Gagliardi, G., Gigantiello, A., SILVESTRI, A. D., Rizzo, A., Mancon, A., Bianchi, M., Poli, F., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2004866 · Cited by 36

The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity

Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 34

Function Is More Reliable than Quantity to Follow Up the Humoral Response to the Receptor-Binding Domain of SARS-CoV-2-Spike Protein after Natural Infection or COVID-19 Vaccination

Sariol, C. A., Pantoja, P., Serrano-Collazo, C., Rosa-Arocho, T., Armina-Rodríguez, A., Cruz, L. A., Stone, E. T., Arana, T., Climent, C., Latoni, G., et al. (2021) · Viruses · doi:10.3390/v13101972 · Cited by 31

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36

Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected

Gidari, A., Sabbatini, S., Bastianelli, S., Pierucci, S., Busti, C., Monari, C., Pasqua, B. L., Dragoni, F., Schiaroli, E., Zazzi, M., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.019 · Cited by 34

Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences

Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 30

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron VariantPreprint

Lyke, K. E., Atmar, R. L., Islas, C. P. D., Posavad, C. M., Szydlo, D. W., PaulChourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4061187 · Cited by 31

Waning and boosting of antibody Fc-effector functions upon SARS-CoV-2 vaccination

Tong, X., McNamara, R. P., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Bertera, H. L., Chicz, T. M., Lévican, J., Poblete, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39189-8 · Cited by 38

SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans

Forgacs, D., Jang, H., Abreu, R. B., Hanley, H. B., Gattiker, J. L., Jefferson, A. M., & Ross, T. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728021 · Cited by 30

Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection

Garrett, M. E., Galloway, J. G., Wolf, C., Logue, J. K., Franko, N., Chu, H. Y., Matsen, F. A., IV, & Overbaugh, J. (2022) · eLife · doi:10.7554/elife.73490 · Cited by 32

Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality

Barkoff, A., Knuutila, A., Mertsola, J., & He, Q. (2021) · Toxins · doi:10.3390/toxins13080508 · Cited by 30

Neutralizing antibody: a savior in the Covid-19 disease

Gupta, S. L., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-07020-6 · Cited by 28

Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission

Ganti, K., Ferreri, L. M., Lee, C.-Y., Bair, C. R., Delima, G. K., Holmes, K. E., Suthar, M. S., & Lowen, A. C. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010181 · Cited by 28

Detection of Major SARS-CoV-2 Variants of Concern in Clinical Samples via CRISPR-Cas12a-Mediated Mutation-Specific Assay

Liang, Y., Zou, L., Lin, H., Li, B., Zhao, J., Wang, H., Sun, J., Chen, J., Mo, Y., Yang, X., et al. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00643 · Cited by 28

Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay

Nam, M., Seo, J. D., Moon, H.-W., Kim, H., Hur, M., & Yun, Y.-M. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01202-21 · Cited by 27

Research progress on vaccine efficacy against SARS-CoV-2 variants of concern

Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 30

Detection of neutralizing antibodies against multiple SARS-CoV-2 strains in dried blood spots using cell-free PCR

Danh, K., Karp, D. G., Singhal, M., Tankasala, A., Gebhart, D., Cortez, F. D. J., Tandel, D., Robinson, P. V., Seftel, D., Stone, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31796-1 · Cited by 27

The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Kashiwakura, Y., Baatartsogt, N., Yamazaki, S., Nagao, A., Amano, K., Suzuki, N., Matsushita, T., Sawada, A., Higasa, S., Yamasaki, N., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.014 · Cited by 27

Interpretable and Predictive Deep Neural Network Modeling of the SARS-CoV-2 Spike Protein Sequence to Predict COVID-19 Disease Severity

Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27

Factors Affecting the Antibody Immunogenicity of Vaccines against SARS-CoV-2: A Focused Review

Cheng, Z. J., Xue, M., Zheng, P., Lyu, J., Zhan, Z., Hu, H., Zhang, Y., Zhang, X. D., & Sun, B. (2021) · Vaccines · doi:10.3390/vaccines9080869 · Cited by 26

Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees

Garziano, M., Utyro, O., Poliseno, M., Santantonio, T. A., Saulle, I., Strizzi, S., Caputo, S. L., Clerici, M., Introini, A., & Biasin, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.820250 · Cited by 23

The Coming of Age of Nucleic Acid Vaccines during COVID-19

Rando, H. M., Lordan, R., Kolla, L., Sell, E., Lee, A. J., Wellhausen, N., Naik, A. S., Kamil, J. P., Gitter, A., Greene, C. S., et al. (2023) · mSystems · doi:10.1128/msystems.00928-22 · Cited by 30

Quantifying the role of naturally- and vaccine-derived neutralizing antibodies as a correlate of protection against COVID-19 variantsPreprint

Cohen, J. A., Stuart, R. M., Rosenfeld, K., Lyons, H. M., White, M. T., Kerr, C. C., Klein, D. J., & Famulare, M. (2021) · medRxiv · doi:10.1101/2021.05.31.21258018 · Cited by 21

Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines

Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21

COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines

Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25

Towards an optimal monoclonal antibody with higher binding affinity to the receptor-binding domain of SARS-CoV-2 spike proteins from different variants

Neamțu, A., Mocci, F., Laaksonen, A., & da Silva, F. L. B. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112986 · Cited by 23

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concernPreprint

Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J., & Peiffer‐Smadja, N. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/z4x7t · Cited by 22

Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern

Xie, T., Lu, S., He, Z., Liu, H., Wang, J., Tang, C., Yang, T., Yu, W., Li, H., Yang, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00920-4 · Cited by 20

SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?

Stasi, C., Meoni, B., Voller, F., & Silvestri, C. (2022) · Vaccines · doi:10.3390/vaccines10030444 · Cited by 20

Comparison of Five Commercial Anti-SARS-CoV-2 Total Antibodies and IgG Immunoassays after Vaccination with BNT162b2 mRNA

Danese, E., Montagnana, M., Salvagno, G. L., Gelati, M., Peserico, D., Pighi, L., NITTO, S. D., Henry, B. M., Porru, S., & Lippi, G. (2021) · Journal of Medical Biochemistry · doi:10.2139/ssrn.3810946 · Cited by 18

In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein

Kathwate, G. H. (2022) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-021-10348-z · Cited by 18

Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil

Bichara, C. D. A., Queiroz, M. A. F., Amoras, E. D. S. G., Vaz, G. L., Vallinoto, I. M. V. C., Bichara, C. N. C., do Amaral, I. P. C., Ishak, R., & Vallinoto, A. C. R. (2021) · Vaccines · doi:10.3390/vaccines9101169 · Cited by 29

Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022

Li, J., Song, R., Yuan, Z., Xu, Z., Suo, L., Wang, Q., Li, Y., Gao, Y. L., Li, X., Chen, X., et al. (2022) · Vaccines · doi:10.3390/vaccines10081215 · Cited by 17

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern

McNamara, R. P., Maron, J. S., Boucau, J., Roy, V., Webb, N. E., Bertera, H. L., Barczak, A. K., Staff, T., Franko, N., Logue, J. K., et al. (2023) · mBio · doi:10.1128/mbio.00902-23 · Cited by 17

COVID-19 mutations: An overview

Sarkar, M. S., & Madabhavi, I. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i3.89761 · Cited by 22

Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination

Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 18

Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants

Liao, G., Lau, H., Liu, Z., Li, C., Xu, Z., Qi, X., Zhang, Y. L., Feng, Q., Li, R., Deng, X., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01940-w · Cited by 15

Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development

Gupta, D., Kumar, M., Sharma, P., Mohan, T., Prakash, A., Kumari, R., & Kaur, P. (2022) · Vaccines · doi:10.3390/vaccines11010023 · Cited by 14

Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Chong, Z. X., Liew, W.-P.-P., Ong, H. K., Yong, C. Y., Shit, C. S., Ho, W. Y., Ng, S., & Yeap, S. K. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153565 · Cited by 13

Correlation of vaccine‐elicited antibody levels and neutralizing activities against SARS‐CoV‐2 and its variants

Liu, J., Bodnar, B. H., Padhiar, N. H., Khan, A. I., Meng, F., Saribas, S., Wang, P., Wang, X., McCluskey, E., Shah, S., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.644 · Cited by 11

Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants

Vogrig, M., Berger, A.-E., Bourlet, T., Waeckel, L., Haccourt, A., Chanavat, A. H., Hupin, D., Roche, F., Botelho-Nevers, É., Pozzetto, B., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01354-x · Cited by 13

Neutralizing-antibody response to SARS-CoV-2 for 12 months after the COVID-19 workplace outbreaks in Japan

Ishizaki, A., Bi, X., Nguyen, Q. T., Maeno, T., Hara, A., Nakamura, H., Kuramoto, S., Nishi, K., Ooe, H., & Ichimura, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273712 · Cited by 11

Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-AnalysisPreprint

Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3858816 · Cited by 11

Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19

Chen, S., Zhang, C., Chen, D., Dong, L., Chang, T., & Tang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200289 · Cited by 14

Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles

Gaikwad, H. K., Li, Y., Wang, G., Li, R., Dai, S., Rester, C., Kedl, R. M., Saba, L. M., Banda, N. K., Scheinman, R. I., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c02794 · Cited by 10

Structural basis of Omicron immune evasion: A comparative computational study

Contractor, D., Globisch, C., Swaroop, S., & Jain, A. K. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105758 · Cited by 10

Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing

O’Shea, K. M., Schuler, C. F., IV, Chen, J., Troost, J. P., Wong, P. T., Chen, K., O’Shea, D. R., Peng, W., Gherasim, C., Manthei, D. M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055429 · Cited by 8

COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004)Preprint

Muñoz, F. M., Posavad, C. M., Richardson, B. A., Badell, M. L., Bunge, K. E., Mulligan, M. J., Parameswaran, L., Kelly, C. W., Olsen-Chen, C., Novák, R., et al. (2022) · medRxiv · doi:10.1101/2022.06.13.22276354 · Cited by 9

Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants After Infections

Kurahashi, Y., Sutandhio, S., Furukawa, K., Tjan, L. H., Iwata, S., Sano, S., Tohma, Y., Ohkita, H., Nakamura, S., Nishimura, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.773652 · Cited by 9

Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico

Cervantes-Luévano, K., Espino‐Vázquez, A. N., Flores-Acosta, G. I., Bernáldez-Sarabia, J., Cabanillas-Bernal, O., Gasperin-Bulbarela, J., González-Sánchez, R., Comas‐García, A., & Licea-Navarro, A. F. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269032 · Cited by 10

Amino acids 484 and 494 of SARS-CoV-2 spike are hotspots of immune evasion affecting antibody but not ACE2 bindingPreprint

Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.22.441007 · Cited by 8

Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variantsPreprint

Edara, V. V., Patel, M., & Suthar, M. S. (2022) · medRxiv · doi:10.1101/2022.01.24.22269189 · Cited by 8

Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage

Gupta, S. L., & Jaiswal, R. K. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07493-z · Cited by 7

Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants

Glab-ampai, K., Kaewchim, K., Saenlom, T., Thepsawat, W., Mahasongkram, K., Sookrung, N., Chaicumpa, W., & Chulanetra, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126587 · Cited by 7

Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination

Fraley, E., Khanal, S., Pierce, S. H., LeMaster, C., McLennan, R., Pastinen, T., & Bradley, T. (2022) · Vaccines · doi:10.3390/vaccines10091477 · Cited by 8

Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility

Trombetta, C. M., Marchi, S., Leonardi, M., Stufano, A., Lorusso, E., Montomoli, E., Decaro, N., Buonvino, N., & Lovreglio, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153537 · Cited by 6

COVID-19 vaccine coverage, safety, and perceptions among patients with diabetes mellitus in China: a cross-sectional study

Li, H., Ping, F., Li, X., Wang, Z., Xiao, J., Jiang, H., Xue, Y., Quan, J., Yao, H., Zheng, X., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1172089 · Cited by 7

Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak

El‐Shesheny, R., Taweel, A. E., Gomaa, M. R., Roshdy, W. H., Kandeil, A., Webby, R. J., Kayali, G., & Ali, M. A. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.086 · Cited by 7

A new strategy to HER2-specific antibody discovery through artificial intelligence-powered phage display screening based on the Trastuzumab framework

Zhang, M., Yang, Q., Lou, J., Hu, Y., & Shi, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167772 · Cited by 6

Combinations but Not a Single PlpE Epitope Induces Host Protective Immunity against Pasteurella multocida

Zhu, W., BangHui, Z., Chen, L., Zhao, J., & Rao, H. (2023) · Infection and Immunity · doi:10.1128/iai.00272-22 · Cited by 6

Neutralizing antibody response to SARS-CoV-2 persists 9 months post symptom onset in mild and asymptomatic patients

Bylicki, O., Delarbre, D., Mayet, A., Ferrier, A., Périsse, A., Malle, C., Cobola, J., Bronstein, A., Menoud, N., Valero-Biance, E., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.002 · Cited by 6

Potential of Antibody-Dependent Cellular Cytotoxicity in Acute and Recovery Phases of SARS-CoV-2 Infection

Cui, T., Huang, M., Su, X., Lin, Z., Zhong, J., Yang, X., & Wang, Z. (2022) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000053 · Cited by 6

Neutralizing antibody responses to SARS-CoV-2: A population based seroepidemiological analysis

Sharma, P., Gupta, E., Basu, S., Agarwal, R., Mishra, S., Kale, P. R., Mundeja, N., Charan, B. S., Singh, G. K., & Singh, M. M. (2022) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2022.07.009 · Cited by 6

Mutational Analysis of Circulating Omicron SARS-CoV-2 Lineages in the Al-Baha Region of Saudi Arabia

Almalki, S. S. R., Izhari, M. A., Alyahyawi, H. E., Alatawi, S. K., Klufah, F., Ahmed, W. A. M., & Alharbi, R. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s419859 · Cited by 6

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan

Kang, C., Lee, N., Lin, C.-H., Hsu, Y., Chang, Y.-C., Chung, M., Lee, Y.-F., Tseng, W.-P., Wu, J.-L., Chen, S., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105156 · Cited by 6

One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection

Dimeglio, C., Hérin, F., Miédougé, M., Da-Silva, I., Porcheron, M., Martin‐Blondel, G., Soulat, J., & Izopet, J. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.06.016 · Cited by 6

COVID-19: Failure of the DisCoVeRy Clinical Trial, and Now–New Hopes?

Eynde, J. J. V. (2021) · Pharmaceuticals · doi:10.3390/ph14070664 · Cited by 5

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina

Rodríguez, P. E., Silva, A. P., Miglietta, E. A., Rall, P., Pascuale, C. A., Ballejo, C., Miranda, L. A. L., Ríos, A. S., Ramis, L. Y., Marro, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992370 · Cited by 5

Efficacy and Safety of Mesenchymal Stem Cells for COVID-19 Infection: A Meta-Analysis and Systematic Review

Chen, L., Xu, Q., Sheng, F., & Wang, B. (2023) · Discovery Medicine · doi:10.24976/discov.med.202335175.21 · Cited by 5

Genomic analysis of SARS-CoV-2 variants: diagnosis and vaccination challenges

Abbasi, H., Behrouzikhah, M., Divbandi, M., Tabaraei, A., Khosravi, A., & Nikoo, H. R. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2252069 · Cited by 4

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease

Otten, A. T., Bourgonje, A. R., Horinga, P. P., van der Meulen, H. H., Festen, E. A. M., van Dullemen, H. M., Weersma, R. K., van Leer‐Buter, C., Dijkstra, G. D. H., & Visschedijk, M. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920333 · Cited by 4

SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients

Chensue, S. W., Siler, A. F., Kim, P. S., Dimcheff, D. E., Daghfal, D., Prostko, J. C., Frias, E. C., Linder, K. A., & Schildhouse, R. J. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02747-22 · Cited by 4

Investigating antigenic features of the SARS-CoV-2 isolated in Russian Federation in 2021–2022 by hyperimmune mouse serum neutralisation

Zaykovskaya, A. V., Evseenko, V. A., Olkin, S. E., & Pyankov, O. V. (2023) · Russian Journal of Infection and Immunity · doi:10.15789/2220-7619-iaf-1998 · Cited by 4

The impact of COVID-19 vaccination on psychiatric symptoms in schizophrenia patients: A retrospective study

Wu, X., Gao, Y., Cheng, X., & Lin, X. (2023) · Medicine · doi:10.1097/md.0000000000034016 · Cited by 4

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants

Ibarrondo, F. J., Hofmann, C., Ali, A., Ayoub, P., Kohn, D. B., & Yang, O. O. (2021) · mBio · doi:10.1128/mbio.02656-21 · Cited by 17

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 102

Costs at the End of Life

Ernecoff, N. C., & Stearns, S. C. (2018) · North Carolina Medical Journal · doi:10.18043/ncm.79.1.43 · Cited by 2

Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination

Bonura, F., Genovese, D., Amodio, E., Calamusa, G., Sanfilippo, G. L., Cacioppo, F., Giammanco, A., Grazia, S. D., & Ferraro, D. (2022) · Vaccines · doi:10.3390/vaccines10060874 · Cited by 8